Two National Guard members shot near White House
DUBLIN - Goldman Sachs & Co. LLC has disclosed its trading position in Avadel Pharmaceuticals PLC, reporting a 1.07% long position and a 0.58% short position in the company’s ordinary shares as of November 25, 2025.
According to a regulatory filing with the Irish Takeover Panel under Rule 38.5(b), Goldman Sachs held 962,709 relevant securities representing 0.98% of Avadel’s shares in long positions, along with derivatives accounting for an additional 0.08%. The firm’s short position consisted of 506,294 shares (0.51%) and derivatives representing 0.06%.
The disclosure detailed multiple transactions conducted on November 25, including purchases of Avadel shares at prices ranging from $22.93 to $22.97 per share. The filing also documented various securities lending activities, including new borrowings of 131,100 shares and several partial returns of borrowed shares.
Goldman Sachs indicated in the filing that it serves as an advisor to Avadel Pharmaceuticals, which explains the required disclosure under Irish takeover rules that govern principal traders connected to companies involved in potential acquisition activities.
The filing included supplemental information about open derivative positions, including swap contracts expiring in December 2025 and January 2026.
This information was provided in a regulatory press release submitted to the London Stock Exchange’s news service.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.